[Form 4] Nuvation Bio Inc. Insider Trading Activity

Rhea-AI Filing Summary

Nuvation Bio Inc. (NUVB) Chief Scientific Officer reported option exercises and same-day share sales. On 11/20/2025, the insider exercised 69,051 stock options at $1.74 per share and 300,000 stock options at $1.94 per share, receiving the same number of Class A common shares.

That same day, the insider sold 69,051 and 300,000 Class A common shares at a weighted-average price of $7.227 per share in separate transactions, leaving 0 shares of common stock directly owned afterward. Following these transactions, the insider continued to hold 229,884 options with a $1.74 exercise price expiring on 01/21/2030 and 200,000 options with a $1.94 exercise price expiring on 02/27/2033.

Insider Trade Summary

Exercise and Sale: 369,051 shares ($1.96M approx. pre-tax spread)

Exercise and Sale 6 txns

Insider Hattersley Gary

Role CHIEF SCIENTIFIC OFFICER

Sold 369,051 shs ($2.67M)

Approx. gross sale proceeds $2.67M

Approx. exercise cost $702K

Approx. pre-tax spread $1.96M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	69,051	$0.00	$0.00
Exercise	Stock Option (Right to Buy)	300,000	$0.00	$0.00
Exercise	Class A Common Stock	69,051	$1.74	$120K
Sale	Class A Common Stock	69,051	$7.227	$499K
Exercise	Class A Common Stock	300,000	$1.94	$582K
Sale	Class A Common Stock	300,000	$7.227	$2.17M

Holdings After Transaction: Stock Option (Right to Buy) — 429,884 shares (Direct); Class A Common Stock — 0 shares (Direct)

Footnotes (3)

1. F1. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.
2. F2. Options vested as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.
3. F3. Options vested as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/24/2025 - 04:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Hattersley Gary

(Last) (First) (Middle)

C/O NUVATION BIO INC.

1500 BROADWAY, SUITE 1401

(Street)

NEW YORK NY 10036

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nuvation Bio Inc. [ NUVB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF SCIENTIFIC OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	11/20/2025		M		69,051	A	$1.74	69,051	D
Class A Common Stock	11/20/2025		S		69,051	D	$7.227(1)	0	D
Class A Common Stock	11/20/2025		M		300,000	A	$1.94	300,000	D
Class A Common Stock	11/20/2025		S		300,000	D	$7.227(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.74	11/20/2025		M			69,051	(2)	01/21/2030	Class A Common Stock	69,051	$0	229,884	D
Stock Option (Right to Buy)	$1.94	11/20/2025		M			300,000	(3)	02/27/2033	Class A Common Stock	300,000	$0	200,000	D

Explanation of Responses:

1. Price reported is a weighted-average sales price. The shares were sold at prices ranging from $7.15 to $7.43. The Reporting Person will provide, upon request, to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

2. Options vested as to 25% on July 1, 2020 and in equal monthly installments thereafter over the following three years.

3. Options vested as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.

	/s/ Stephen Dang, Attorney-in-Fact	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.